(Photo courtesy DiPole Materials.)
A Baltimore company has a new product that’s designed to put cells in their natural habitat during tests.
BioPapers, recently launched by nanofiber manufacturing company DiPole Materials, can be used by pharmaceutical companies during drug discovery, as well as tissue engineering and 3D bioprinting, said DiPole CEO Ken Malone.
The product is designed to made of very thin fibers of the protein gelatin. The nanofibers can be treated to create a scaffold that is similar to the environment in which a cell grows inside the body. This makes it distinct from synthetic environments like cell culture plates, Malone said.
“Our customers needed a standardized scaffold that made cells behave like they do inside the human body. They were frustrated that the only available scaffolds were of synthetic materials which caused cells to misbehave,” DiPole cofounder Scott Gaboury said.
So far, Malone said the company has found the most traction from big pharmaceutical companies, which would use the BioPapers to screen hundreds and thousands of drugs. The sheets sold to the pharma companies look like this:
“Each well has a piece of BioPaper in it,” Malone said. “Our pharma customers grow cells on the paper, then put drops of various drugs onto those cells and determine toxicity or efficacy of the drugs from it.”
Other applications could include tissue engineering for growth of stem cells. It could also be used as the “paper” that is used during 3D bioprinting, Malone said.
BioPapers are made using a process called electrospinning, which draws an electric charge to create fibers. The machinery is the same DiPole used to produce a piezoelectric yarn that the company is also currently developing and could be used in smart garments. Here’s what the nanofibers look like under a microscope:
Malone said the team discovered work on BioPapers at the U.S. Naval Research Laboratory in D.C., and later licensed the technology. It received funding through TEDCO’s Technology Validation Program to develop the concept, and investment from the Abell Foundation helped get it to launch, Malone said.
Now, production is located within Harbor Designs and Manufacturing space at the Wicomico building in Pigtown. Harbor, which performs contract manufacturing for various companies including medical device makers, has offered some Baltimore startups the option to colocate within the recently-expanded facility.
Malone said there’s plenty of capacity to manufacture the volumes required over the first couple years of production.
Columbia-based Osiris Therapeutics to be acquired in $660M deal
Partnering with French firm, Early Charm Ventures looks to European market
Gliknik receives $15M payment from Pfizer after reaching clinical milestone
At 14 West, only go-getters need apply
JHU spinout WindMIL Therapeutics expands to Philly, adds two new executives
Baltimore biotech company partners with JuiceBot on food safety
Meet the Baltimore entrepreneur who earned a finalist spot at the first Lyft Pitch
Learn to lead digital transformation at Phorum 2019
Sign-up for daily news updates from Technical.ly Baltimore